Zhejiang Jingxin Pharmaceuticals received CFDA approval issued by the heavy lig litadine kabaratin capsule drug registration approval

yesterday, Zhejiang Jing
new drug(limited shares
of the company
(issued a notice that the company has received the State Food and Drug Administration approved the issuance of heavy lignin kabaratin capsules (specifications 1.5mg and 3.0mg)drug(registered approval, approval document number is the national drug code H20183124 and the national drug code H20183125)on heavy lig litanacinAccording to data, heavy lig litaline kabaratin is a first-linedrugdeveloped by Novartis of Spain for the treatment of mild, moderate Alzheimer's dementia (has been on the market in China for many years)Compared to similar drugsthe treatment index of matsalitin is high, and the use of antipsychotic drugs and complementary statins can be significantly reduced during treatment, the clinical efficacy is significant, and has broad application prospects in the field of Alzheimer's dementia treatmentAt present, Jingxin Pharmaceuticals is the firstmanufacturer in China to obtain the batch of heavy lig-satric acid kabaratin capsule production(and the company's first treatment for Alzheimer's dementia drugs, this approval will have a positive impact on the company's pharmaceutical business.)